Navigation Links
Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
Date:10/25/2007

Primary Analysis of Pivotal Trial to Be Available No Later Than July 2008

SAN DIEGO, Oct. 25 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq: FVRL), a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, announced that an independent Data Monitoring Board (DMB) was recently convened to assess time to tumor progression (TTP) for patients in the control group of the Company's pivotal Phase 3 clinical trial of FavId(R). The DMB assessment, which was conducted in accordance with the clinical protocol under Favrille's Special Protocol Assessment (SPA) with the Food & Drug Administration (FDA), indicated that the control group behavior is consistent with data reported in the published literature. Based in part on the guidance provided by the DMB, Favrille has determined April 2008 to be the appropriate time for data cutoff of the Phase 3 trial. The Company anticipates that the analysis of the data will be completed and made available no later than July 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGO)

The Phase 3 trial is a randomized, double-blind, placebo controlled trial of FavId following Rituxan(R) treatment in patients with follicular B-cell non-Hodgkin's lymphoma (NHL). A total of 349 patients were randomly assigned to receive either FavId plus Leukine(R) (sargramostim, GM-CSF) or placebo plus Leukine following a course of Rituxan treatment. The primary endpoint of this trial is TTP.

"As we previously communicated, the rate of progression in our pivotal Phase 3 trial has slowed during the past 12 months," said John P. Longenecker, Ph.D., President and Chief Executive Officer of Favrille. "We believe this is a positive development, and it has shifted our focus for data cutoff and analysis to trial follow-up time as allowed in the protocol rather than the number of patient progressi
'/>"/>

SOURCE Favrille, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkins Lymphoma in Europe
2. Favrille Announces Results From Study Showing Enhanced Activity From Insect Cell-Derived Immunotherapy for Lymphoma
3. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
4. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
5. XTL Provides Update on Phase I Clinical Trial of XTL-2125
6. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
7. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
8. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
9. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
10. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
11. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... NEW YORK , June 18, 2013 JDRF ... ) are accelerating the development of new products that combine ... new collaboration announced today. This new, three-year commitment is an ... (T1D). Many patients with T1D not only take ... to be placed in the body for a number of ...
(Date:6/18/2013)... EMERYVILLE, Calif. , June 18, 2013 ... today from a Phase 2/3 clinical trial of ... statistically significant improvement in levodopa-induced dyskinesia (LID) as ... versus placebo in the Unified Dyskinesia Rating Scale ... amantadine intended for once-nightly administration that is being ...
(Date:6/17/2013)... ANGELES , June 17, 2013 Velplex, ... TopProdeals.com , a technology platform that connects buyers and ... into being an industry leader. Why? ... at TopProdeals™ are intimately familiar with the dental industry. ... healthcare community and have diligently worked to negotiate some ...
Breaking Medicine Technology:JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring Products for People with Type 1 Diabetes 2JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring Products for People with Type 1 Diabetes 3Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 2Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 3Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 4Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 5Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 6TopProdeals.com Rises to Top as Discount Dental Supply Leader 2
... ALLENTOWN, Pa., Jan. 9, 2012    Lehigh Valley Technologies, ... of a recently completed inspection by the U.S. ... 2011, FDA completed an onsite inspection with no ... that there were no negative observations relating to ...
... 9, 2012 Uptake Medical ® today announced ... round. The round was led by Singapore-based Crescent Point ... Venture Partners, WRF Capital, Arboretum Ventures and Affinity Capital, ... will join the Uptake Medical board of directors. Moelis ...
Cached Medicine Technology:Uptake Medical Announces Successful Completion of Series C Financing 2
(Date:6/18/2013)... New York (PRWEB) June 18, 2013 As ... both state and federal court, a new report has revealed ... than 70,000 U.S. Food & Drug Administration (FDA) adverse event ... to NewsChannel5 in Cleveland, Ohio, over 4.700 Mirena users have ... while more than 1,300 have reportedly experienced uterine perforations due ...
(Date:6/18/2013)... York, N.Y., June 18, 2013 -- Lauren Sciences, ... novel V-Smart nanovesicle platform technology, announced today that ... in Drug Delivery with its V-Smart Platform, and ... report by MCD Group. , The ... of Start-ups and Emerging Companies ," features companies ...
(Date:6/18/2013)... Lesbian, Gay, Bisexual and Transgender (LGBT) Pride ... sexual minority youth are still at greater ... according to the Suicide Prevention Resource Center. ... recently published recommendation to improve psychologists, treatment ... improve psychological functioning and reduce depression and ...
(Date:6/18/2013)... 18, 2013): With Medicare penalties on hospitals with ... in 2014, more hospitals are evaluating the most ... A new study appearing in the June issue ... of Surgeons finds that the American College ... NSQIP) led to more accurate data tracking than ...
(Date:6/18/2013)... June 18, 2013 Two weeks ago, eyes ... Philadelphia, Pennsylvania. As reported by CNN on ... building collapse, 13 injured," a building scheduled to be demolished ... shop, and six of those persons succumbed to their injuries. ... the country. , The situation should serve as a reminder ...
Breaking Medicine News(10 mins):Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Mounting Reports of Mirena Side Effects, Including Device Migration, Uterine Perforations 2Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Mounting Reports of Mirena Side Effects, Including Device Migration, Uterine Perforations 3Health News:Sexual minority youth need specialized treatment from therapists 2Health News:ACS NSQIP® data is more accurate than administrative data for tracking 30-day hospital readmissions 2Health News:ACS NSQIP® data is more accurate than administrative data for tracking 30-day hospital readmissions 3Health News:ACS NSQIP® data is more accurate than administrative data for tracking 30-day hospital readmissions 4Health News:Ensuring The Safety of Pennsylvania Worksites 2Health News:Ensuring The Safety of Pennsylvania Worksites 3
... 28, 2010) Errors in diagnosis place a heavy ... and can be devastating for affected patients. Strengthening ... comprehensive and coordinated primary care could potentially address this ... from Baylor College of Medicine ( www.bcm.edu ) and ...
... Langone Medical Center has begun a clinical trial offering ... This novel, minimally invasive procedure uses a light-activated ... laser fibers in order to destroy prostate cancer cells. ... prostate cancer offers the potential to destroy the cancer ...
... rural hospitals may be quicker and more efficient at ... and are capable of providing a standard of surgical ... provide a comprehensive array of care services, according to ... the University of Louisville Department of Surgery. "The ...
... One of the human body,s most powerful defensive tools, ... toxins and viruses in the bloodstream from reaching the ... of physicians to deliver drugs directly to the brain, ... Rensselaer Polytechnic Institute are endeavoring to solve this problem ...
... Germany, several national health campaigns promote cancer screening by announcing ... is supposed to motivate men to have an examination. But ... journal of the Association for Psychological Science, finds that this ... less likely to choose to get screened. In ...
... Reinberg HealthDay Reporter , MONDAY, July 26 ... cancers, those whose level of prostate-specific antigen (PSA) is ... new study shows. Recent evidence has shown that ... the cancer they die from, but another condition. For ...
Cached Medicine News:Health News:Reform of primary care could reduce diagnostic errors 2Health News:Reform of primary care could reduce diagnostic errors 3Health News:Reform of primary care could reduce diagnostic errors 4Health News:NYU Langone offers vascular-targeted photodynamic therapy for localized prostate cancer 2Health News:Smaller hospitals can provide safe and high-quality surgical care comparable to larger counterparts 2Health News:Smaller hospitals can provide safe and high-quality surgical care comparable to larger counterparts 3Health News:Breaching the blood-brain barrier to create powerful new tools for fighting cancer 2Health News:Breaching the blood-brain barrier to create powerful new tools for fighting cancer 3Health News:Few people are doing it, so why should I? Motivating men to seek cancer screening 2Health News:Most Men With Low-Risk Prostate Cancer Treated Aggressively, Study Shows 2Health News:Most Men With Low-Risk Prostate Cancer Treated Aggressively, Study Shows 3
... and Response catheters comprise the world's ... for electrophysiology procedures. Their advanced catheter ... superior torque response with a soft, ... and French sizes, Supreme and Response ...
Lumenis 950 Slit Lamp Zeiss-style diagnostic slit lamp biomicroscope with parallel optics and offering a choice of automatic or fixed eye safety filters for multiple wavelengths....
... Nd:YAG Base Platform is an ... the anterior segment of the ... of secondary cataracts and performing ... offers multiple upgrade options that ...
... Catheter Delivery System (CDS) facilitates ... of the Aescula LV Left-Heart ... a patented coronary sinus curve ... easy access to the coronary ...
Medicine Products: